Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

IMPORTANCE: KRAS mutations are very common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways downstream of the KRAS protein as an alternate treatment strategy to slow cancer growth and prolon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Chung, Vincent, McDonough, Shannon, Philip, Philip A., Cardin, Dana, Wang-Gillam, Andrea, Hui, Laifong, Tejani, Mohamedtaki A., Seery, Tara E., Dy, Irene A., Baghdadi, Tareq Al, Hendifar, Andrew E., Doyle, L. Austin, Lowy, Andrew M., Guthrie, Katherine A., Blanke, Charles D., Hochster, Howard S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665683/
https://ncbi.nlm.nih.gov/pubmed/27978579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.5383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados